GSK Sues Over Genentech Antibody Patent

Law360, New York (October 8, 2009, 6:04 PM EDT) -- GlaxoSmithKline has filed a suit in federal court challenging the validity of a patent belonging to rival Genentech Inc. as it prepares to release a cancer drug.

GSK filed a complaint Thursday in the U.S. District Court for the Southern District of Florida, asking for a declaratory judgment that Genentech's “Cabilly” patent is invalid and not infringed by GSK's Arzerra, the brand name of the drug ofatumumab.

GSK and partner GenMab submitted a biologics license application to U.S. Food and Drug Administration in January, asking permission...
To view the full article, register now.